Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study-Reference-Cited by-同舟云学术

Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study

Published:2022-12 Issue: Volume:67 Page:101502
ISSN:1096-6374
Container-title:Growth Hormone & IGF Research
language:en
Short-container-title:Growth Hormone & IGF Research

Author:

Durmuş Elif Tutku,Atmaca Ayşegül,Kefeli Mehmet,Çalışkan Sultan,Mete Ozgur,Aslan Kerim,Fidan Murat,Çolak Ramis,Durmuş Buğra

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Reference37 articles.

1. Acromegaly: an endocrine society clinical practice guideline;Katznelson;J. Clin. Endocrinol. Metab.,2014

2. A consensus statement on acromegaly therapeutic outcomes;Melmed;Nat. Rev. Endocrinol.,2018

3. A pituitary society update to acromegaly management guidelines;Fleseriu;Pituitary.,2021

4. Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly;Heck;Endocrine.,2016

5. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience;Brzana;Pituitary.,2013

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical implications of the 2022 WHO classification on the multidisciplinary management of PitNETS patients;Minerva Endocrinology;2024-07

2. Personalized Medicine in Acromegaly: The ACROFAST Study;The Journal of Clinical Endocrinology & Metabolism;2024-06-29

3. Predictors of morphofunctional features of somatotrophic tumors and of the effectiveness of treatment with first-generation somatostatin receptor ligands;Meditsinskiy sovet = Medical Council;2024-05-19

4. Immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in Acromegaly;Journal of Neuro-Oncology;2024-03-05

5. New molecular tools for precision medicine in pituitary neuroendocrine tumors;Minerva Endocrinology;2024-01